What are the Chemotherapeutic Options for Women with Advanced or Recurrent Endometrial Cancers?

For patients with cancer cells that originally arose from the lining of the womb who do not show symptoms of cancer and only have small tumours, it is recommended to begin treatment of the cancer with hormonal therapy.

A disease causing symptoms to be experienced by the patient or a high-grade disease with large tumours should be treated with chemotherapy consisting of platinum and taxane combined. A taxane is a drug that inhibits cancer growth. The use of taxane-platinum-based chemotherapy should be considered as standard of care (compared to platinum-non-taxane); while the use of hormones can be considered. Hormonal therapy should only be used for patients with cancer cells that originally arose from the lining of the womb.

Carboplatin and paclitaxel are preferred as the first-line chemotherapy regimen. Carboplatin is a drug used to treat cancer cells by disrupting cell growth of cancer cells. Paclitaxel belongs to the taxane family of drugs that inhibit cancer growth.

If first-line chemotherapy fails, there is data to support using mTOR inhibitors in patients with endometrioid endometrial cancer that have spread to other sites in the body or relapsed after treatment. mTOR stands for Mechanistic Target Of Rapamycin. mTOR inhibitors target a protein that regulates cell growth, slowing the growth of cancer cells.